319 related articles for article (PubMed ID: 28742138)
1. Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study.
Haga F; Maruko R; Sato C; Kataoka K; Ito Y; Terasaki H
PLoS One; 2017; 12(7):e0181479. PubMed ID: 28742138
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
[TBL] [Abstract][Full Text] [Related]
3. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
[TBL] [Abstract][Full Text] [Related]
5. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
Liu Y; Li L; Xu G; Wang W
Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy.
Tseng CC; Chen SN
Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621
[TBL] [Abstract][Full Text] [Related]
7. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
8. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.
Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT
Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002
[TBL] [Abstract][Full Text] [Related]
9. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
10. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
Kim YK; Ryoo NK; Woo SJ; Park KH
Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
[TBL] [Abstract][Full Text] [Related]
11. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
Matušková V; Vysloužilová D; Uher M
Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
[TBL] [Abstract][Full Text] [Related]
12. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Son BK; Kim K; Kim ES; Yu SY
Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
[TBL] [Abstract][Full Text] [Related]
14. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
[TBL] [Abstract][Full Text] [Related]
15. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
16. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
17. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
Hayashida M; Miki A; Honda S; Nakamura M
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for chronic central serous chorioretinopathy.
Ruiz-Moreno JM; Lugo FL; Armadá F; Silva R; Montero JA; Arevalo JF; Arias L; Gómez-Ulla F
Acta Ophthalmol; 2010 May; 88(3):371-6. PubMed ID: 19958296
[TBL] [Abstract][Full Text] [Related]
19. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
Li L; Yuan F; Xu GZ; Wang WJ
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
[TBL] [Abstract][Full Text] [Related]
20. Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report.
Liu Y; Wang X; Zhu M; Xu G; Li L
BMC Ophthalmol; 2019 Mar; 19(1):68. PubMed ID: 30849939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]